Profound Medical Corp. (TSE:PRN - Free Report) - Equities research analysts at Raymond James issued their Q1 2026 earnings per share (EPS) estimates for shares of Profound Medical in a research note issued to investors on Tuesday, February 18th. Raymond James analyst M. Freeman expects that the company will earn ($0.34) per share for the quarter. Raymond James currently has a "Strong-Buy" rating on the stock. The consensus estimate for Profound Medical's current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical's Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.20) EPS.
Profound Medical Price Performance
Profound Medical stock traded up C$0.09 during mid-day trading on Wednesday, reaching C$10.60. 10,635 shares of the company's stock traded hands, compared to its average volume of 6,813. Profound Medical has a 12-month low of C$7.90 and a 12-month high of C$15.75. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The stock has a 50 day moving average of C$10.03 and a two-hundred day moving average of C$10.83. The company has a market cap of C$223.36 million, a price-to-earnings ratio of -5.50 and a beta of 0.81.
Insider Transactions at Profound Medical
In related news, Senior Officer Thomas Michael Tamberrino bought 13,333 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average price of C$10.65 per share, with a total value of C$141,996.45. Also, Director Arun Menawat Dr. purchased 20,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was bought at an average price of C$10.65 per share, with a total value of C$213,000.00. Insiders own 8.62% of the company's stock.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Further Reading
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
